- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05741086
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS) (EAST-ICAS)
Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Intracranial atherosclerosis stenosis (ICAS) is one of the most common causes of stroke worldwide and is particularly prevalent in Asian. It accounts for up to 30-50% of strokes amongst Asian patient cohorts, in contrast to 5-10% of strokes amongst western patient cohorts. The SAMMPRIS established aggressive medical management (Intensive lipid lowering with statin to reach a low-density lipoprotein (LDL)-cholesterol lower than 1.8mmol/L, et al) as a superior choice for symptomatic ICAS compared to the percutaneous transluminal angioplasty and stenting. However, around 15% still had recurrent stroke or death during a median follow-up of 32.4 months in SAMMPRIS study in the aggressive medical management group.
Evolocumab, a member of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, is a fully human monoclonal antibody that reduces LDL cholesterol levels by approximately 60%. The FOURIER study showed that Evolocumab reduced the risk of cardiovascular events (e.g. cardiovascular death, myocardial infarction and stroke), in patients with atherosclerotic cardiovascular disease.
The proposed pilot study will recruit 80 patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis, and directly compare Evolocumab on top of statin with statin therapy in changes of intracranial atherosclerotic plaque and hemodynamic features during 1 year of follow-up.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Zhaolu Wang, MD
- Phone Number: 18100613663
- Email: wangzhaolu123@163.com
Study Contact Backup
- Name: Kezhong Zhang, MD
- Phone Number: 13770840575
- Email: zhangkezhong8@126.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210001
- Recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Zhaolu Wang, MD, PhD
- Phone Number: 18100613663
- Email: wangzhaolu123@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Age ≥ 30 years and ≤ 75 years.
- TIA or Acute ischemic stroke that occurred within 6 weeks prior to randomization.
- Modified Rankin score of ≤ 4.
- TIA or acute ischemic stroke attributed to a 50 to 99% stenosis of a major intracranial artery (internal carotid artery [ICA], vertebral artery [VA], basilar artery [BA] and the M1 segment of middle cerebral artery [MCA]). The diagnostic evaluation for ICAS at each site is confirmed by the local investigator, using high resolution MR.
To increase the likelihood that the symptomatic intracranial stenosis is atherosclerotic, patients aged 30-49 years are required to meet at least one additional criteria (i-vi) below:
i. insulin dependent diabetes for at least 15 years. ii. at least 2 of the following atherosclerotic risk factors: hypertension (Blood pressure [BP] ≥ 140/90 or on antihypertensive therapy); dyslipidemia (LDL ≥ 130 mg /dl or high density lipoprotein (HDL) < 40 mg/dl or fasting triglycerides ≥150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 for women at the time of the event.
iii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease.
iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic. v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography.
vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic.
- Patient agrees with follow-up visits and is available by phone.
- Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed informed consent.
Exclusion criteria
- Previous treatment of target intracranial lesion with a stent, angioplasty, or other mechanical devices (e.g. mechanical thrombectomy, coil embolization).
- Plan to perform angioplasty, stenting, coiling, thrombectomy, endarterectomy or aneurysmal coil embolization for target vessels/plaques. In case that patients who receive surgeries during follow-up, they will still be followed up for 1 year.
- Intracranial tumor (except meningioma) or any intracranial vascular malformation.
- History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural).
- Intracranial arterial stenosis due to arterial dissection; MoyaMoya disease; any known vasculitic disease; viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with cerebral spinal fluid pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected vasospastic process; reversible cerebral vasoconstriction syndrome (RCVS); suspected recanalized embolus.
- Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.
- Use of cholesteryl ester transfer protein (CETP) inhibition treatment, mipomersen, or lomitapide within 12 months prior to randomization. Fenofibrate therapy must be stable for at least 6 weeks prior to final screening at a dose that is appropriate for the duration of the study in the judgment of the investigator. Other fibrate therapy (and derivatives) are prohibited.
- Prior use of PCSK9 inhibition treatment before this recruitment.
- Known allergy or contraindication to aspirin, clopidogrel, evolocumab or atorvastatin.
- Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets < 100,000, hematocrit < 30, international normalized ratio (INR) > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment (aspartate transaminase [AST] or alanine transaminase [ALT] > 3 x normal, cirrhosis), creatine kinase > 5 times the upper limit of normal (ULN) at final screening, severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 20mL/min/1.73 square meter at final screening.
- Major surgery (including open femoral, aortic, cardiac or carotid surgery) within previous 30 days or planned in the 1 year after enrollment.
- Dementia or psychiatric problem that prevents the patient from relevant evaluation or follow-up reliably.
- Co-morbid conditions that may limit survival to less than 1 year.
- Currently breastfeeding, pregnancy, planning to become pregnant and unwilling to use contraception for the duration of this study
- Enrollment in another study that would conflict with the current study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Evolocumab added to statin therapy
Evolocumab (140 mg every 2 weeks for 1 year) added to statin (Atorvastatin 20-40mg).
Anti-platelet aggregation and risk factor management in both arms.
|
evolocumab (140 mg every 2 weeks)
Atorvastatin 20-40mg
|
Active Comparator: Statin therapy
Atorvastatin 20-40mg.
Anti-platelet aggregation and risk factor management in both arms.
|
Atorvastatin 20-40mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plaque burden (PB)
Time Frame: This will be assessed at 1 year after recruitment.
|
lumen area (LA) is manually contoured on T1-weighted SPACE at the most stenotic site (LAplaque).
PB is calculated as (1 - LAplaque/OWAplauqe) × 100%
|
This will be assessed at 1 year after recruitment.
|
Degree of stenosis caused by the plaque
Time Frame: This will be assessed at 1 year after recruitment.
|
degree of stenosis = (1 - Dplaque/Dreference) × 100%, where Dplaque indicated the diameter of the culprit artery at the most stenotic site, and Dreference was the diameter of the normal artery proximal to the plaque
|
This will be assessed at 1 year after recruitment.
|
Plaque enhancement
Time Frame: This will be assessed at 1 year after recruitment.
|
grading of plaque enhancement: grade 0 indicated enhancement is similar to or less than that of normal-appearing intracranial arterial walls in the same individual; grade 1, enhancement is greater than that of grade 0 but less than that of the pituitary infundibulum; and grade 2, enhancement is similar to or greater than that of the infundibulum.
plaque enhancement ratio (ER): circular region of interest (ROI) was drawn within the plaque on pre-contrast and post-contrast T1-weighted SPACE images, respectively.
The mean signal intensity (SI) of plaques were obtained.
ER = (SIpost - SIpre)/SIpre ×100%
|
This will be assessed at 1 year after recruitment.
|
Remodeling index (RI) of the plaque
Time Frame: This will be assessed at 1 year after recruitment.
|
the outer wall area (OWA) is manually contoured on T1-weighted SPACE at the most stenotic site (OWAplaque) and the reference site (OWAreference).
RI is calculated as OWAplaque/OWAreference × 100%.
Arterial remodeling is categorized as positive if RI > 1.05, intermediate if 0.95 ≤ RI ≤ 1.05, and negative if RI < 0.95;
|
This will be assessed at 1 year after recruitment.
|
Presence of T1 hyperintensity in the plaque
Time Frame: This will be assessed at 1 year after recruitment.
|
the brightest spot of the plaque with SI >150% of that of the reference vessel wall on pre-contrast T1 image
|
This will be assessed at 1 year after recruitment.
|
Plaque distribution: whether it is a concentric plaque or not
Time Frame: This will be assessed at 1 year after recruitment.
|
a concentric plaque is defined if the wall involvement was more than 75%, and the minimum wall thickness is higher than 50% of the maximum wall thickness.
|
This will be assessed at 1 year after recruitment.
|
Hemodynamic characteristics: Hypoperfusion volume
Time Frame: This will be assessed at 1 year after recruitment.
|
dynamic susceptibility contrast-perfusion weighted imaging (DSC-PWI) performed and computed using the singular value decomposition deconvolution method using a commercial software NeuBrainCARE (v1.1.10).
Hypoperfusion volume on the ipsilateral side of stroke were automatically calculated by use of time to maximum (Tmax) with time thresholds of > 4 seconds and > 6 seconds, respectively.
|
This will be assessed at 1 year after recruitment.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
any stroke (ischemic or hemorrhagic) or death during 1 year of follow-up in an intention-to treat analysis.
Time Frame: This will be assessed during the first year of follow-up.
|
This will be assessed during the first year of follow-up.
|
Changes in LDL-cholesterol levels
Time Frame: This will be assessed during the first year of follow-up.
|
This will be assessed during the first year of follow-up.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hua Lu, MD, The First Affiliated Hospital with Nanjing Medical University
Publications and helpful links
General Publications
- Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Lynch JR, Zaidat OO, Rumboldt Z, Cloft HJ; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25;383(9914):333-41. doi: 10.1016/S0140-6736(13)62038-3. Epub 2013 Oct 26.
- Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013 Nov;12(11):1106-14. doi: 10.1016/S1474-4422(13)70195-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathological Conditions, Anatomical
- Constriction, Pathologic
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Protease Inhibitors
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Serine Proteinase Inhibitors
- PCSK9 Inhibitors
- Atorvastatin
- Evolocumab
Other Study ID Numbers
- EAST-ICAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis
-
The First Affiliated Hospital with Nanjing Medical...RecruitingStroke | Intracranial Atherosclerotic StenosisChina
-
B. Braun Medical International Trading Company...RecruitingStroke | Intracranial Atherosclerotic StenosisChina
-
Yale UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Not yet recruitingStroke | Intracranial Atherosclerotic Stenosis (ICAS)United States
-
BochangFirst People's Hospital of Hangzhou; First Affiliated Hospital Xi'an Jiaotong... and other collaboratorsNot yet recruitingIntracranial Atherosclerotic Stenosis
-
liuxingjuNational Clinical Research Center for Neurological DiseasesUnknownAtherosclerotic Intracranial Arterial Stenosis With Intracranial AneurysmsChina
-
Meshalkin Research Institute of Pathology of CirculationFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical... and other collaboratorsRecruitingPatients With Aterosclerotic Carotid Stenosis | Symptomatic Patients (Stenosis > 50%) | Asymptomatic Patients (Stenosis ≥80%)Russian Federation
-
Meshalkin Research Institute of Pathology of CirculationCompletedPatients With Aterosclerotic Carotid Stenosis | Symptomatic Patients (Stenosis > 50%) | Asymptomatic Patients (Stenosis ≥80%)Russian Federation
-
jiaoliqunRecruitingIschemic Stroke | Plaque, Atherosclerotic | Intracranial Atherosclerosis | Artery Stenosis | Optical Coherence TomographyChina
-
Beijing Tiantan HospitalNot yet recruitingTIA | Ischemic Stroke, Acute | Symptomatic Intracranial Artery StenosisChina
-
Sir Mortimer B. Davis - Jewish General HospitalRecruitingPatients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to RadiationCanada
Clinical Trials on Evolocumab
-
Hospital General Universitario Gregorio MarañonCompleted
-
First Affiliated Hospital of Fujian Medical UniversityRecruiting
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
Rigshospitalet, DenmarkWithdrawnLipid Lowering, Vascular InflammationDenmark
-
AmgenOrganization of Teratology Information Specialists (OTIS) Research Center...TerminatedHypercholesterolemia; ASCVD; Pregnancy
-
AmgenCompletedMixed Dyslipidemia | Primary HypercholesterolemiaUnited States, Canada
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
AmgenCompletedHomozygous Familial Hypercholesterolemia HoFHIndia
-
LIB Therapeutics LLCCompletedHomozygous Familial HypercholesterolemiaUnited States, Israel, Norway, South Africa, Turkey, India
-
University Hospital Inselspital, BerneAmgen; University of BernCompletedAcute Coronary SyndromeSwitzerland